Do elevated autoantibodies in patients with multiple sclerosis matter?

Dal‐Bianco, Assunta; Wenhoda, Fritz; Weber, Michael; Altmann, Patrick; Kraus, Jörg; Leutmezer, Fritz; Salhofer‐Polanyi, Sabine

doi:10.1111/ane.13054

Cited by 7 publications

(5 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, only one patient had an autoantibody-related autoimmune disease. In line with the findings of our study, the authors concluded that autoantibody positivity was not associated with disease activity and thus that the results of the autoantibody tests did not have any effect on the diagnosis of any patient with suspected MS, and that routine application of large autoantibody panel was not cost-effective [22].…”

Section: Resultssupporting

confidence: 89%

Clinical significance and prognostic value of serum autoantibody tests in multiple sclerosis

Oncel

Dalkılıç

Sayan

et al. 2024

Neurol Neurochir Pol.

View full text Add to dashboard Cite

Introduction.It is known that multiple sclerosis (MS) often coexists with other autoimmune diseases. Hence, autoantibody (auto-Ab) tests may prove useful in the differential diagnosis of MS. The objectives of this study were to: (a) investigate the prevalence of auto-Ab positivity at the beginning of the MS diagnostic process; (b) assess whether Auto-Ab+ and Auto-Ab-patients differ in baseline clinical, laboratory, and radiological parameters; and (c) investigate the prognostic value during a two-year follow-up period.Material and methods. This retrospective study consisted of 450 patients aged between 18 and 55 years. All patients underwent a wide range of auto-Ab tests, anti-nuclear antibody (ANA) tests in particular. The expanded disability status scale (EDSS) scores of the patients were recorded at the time of diagnosis and at the end of a two-year follow-up period.Results. The mean age of the 212 patients, 148 (69.8%) female and 64 (30.2%) male, included in the study sample was 37 ± 10.83 years. The rate of relapsing cases was 84% (178). Oligoclonal band (OCB) was positive in 142 (86.6%) of the 164 tested cases. At least one of the auto-Ab tests was positive in 51 (24.1%) of the cases. ANA test was positive in 21 (9.9%) cases. There was no significant difference between patients with at least one positive auto-Ab test and without any positive auto-Ab test and between ANA-positive and ANA-negative patients in terms of age, gender, clinical features of MS, presence of brain stem lesion, presence of spinal lesion, OCB positivity, level of clinical improvement after the first pulse steroid treatment, family history, presence of comorbidity, presence of autoimmune disease, or EDSS scores recorded at the end of the two-year follow-up period (p > 0.05). Conclusions.Our study findings revealed that Auto-Ab positivity was more common in MS patients than in the general population. However, given their limited contribution to the diagnosis and differential diagnosis of MS with no effect on the prognostic process, auto-Ab tests should be requested only in the event of accompanying autoimmune disease symptoms, and in cases where the diagnosis of MS may be suspected.

show abstract

Section: Resultssupporting

confidence: 89%

Clinical significance and prognostic value of serum autoantibody tests in multiple sclerosis

Oncel

Dalkılıç

Sayan

et al. 2024

Neurol Neurochir Pol.

View full text Add to dashboard Cite

show abstract

“…On the other hand, the study by Dal-Bianco et al showed that among 176 patients with MS, 18.8% had autoantibodies of autoimmune diseases while in 12.0% of them, an autoimmune disease was actually found. 22 …”

Section: Discussionmentioning

confidence: 99%

The prevalence of autoimmune diseases in patients with multiple sclerosis: A cross-sectional study in Qom, Iran, in 2018

Ershadinia¹,

Mortazavinia²,

Babaniamansour³

et al. 2021

CJN

View full text Add to dashboard Cite

Background: Multiple sclerosis (MS) is one of the most common autoimmune diseases worldwide and various autoimmune comorbidities are reported with MS. The objective of this study is to estimate the prevalence of the autoimmune diseases’ comorbidity in patients with MS. Methods: In this cross-sectional study, we investigated a group of patients with MS in terms of age, gender, duration of MS, presence of simultaneous autoimmune diseases, such as Graves’ disease, Hashimoto’s thyroiditis, type 1 diabetes mellitus (DM), and systemic lupus erythematous (SLE). Results: This study included 1215 patients with MS, of which 70.8% were women. The mean age of participants was 33.70 ± 27.63 years. 55 patients (4.5%) had at least one autoimmune disease. The most common comorbidity was for Hashimoto’s thyroiditis (30 patients). The frequency of simultaneous autoimmune disease was higher in women. Mean age (P = 0.01), mean duration of MS (P = 0.03), and mean age on MS diagnosis (P = 0.02) were significantly higher in simultaneous MS and other autoimmune diseases. Conclusion: Our study revealed that the probability of autoimmune diseases co-occurrence in patients with MS could be higher in older patients, in longer duration of disease, and also in patients with higher age at time of MS diagnosis.

show abstract

“…In patient with MS-positive, ANA reported in around 13% of the patients [7,11]. In a study of 176 individuals with definite MS, testing for autoimmune antibodies were not cost-effective as 18% of the patients had elevated autoimmune antibodies but minority developed another autoimmune disease over 10 years follow-up [8].…”

Section: Discussionmentioning

confidence: 99%

“…A previous study was conducted before 2000 to examine whether patients with MS who were ANA positive should be excluded from clinical trials and reported no difference between patients with MS with low ANA titer and those that were ANA negative [7]. A recent study tried to look at the prevalence of positive autoantibodies in patient with MS in Vienna and reported 18% of the patients with MS had positive autoantibody without having another autoimmune disease [8]. However, these findings could not be generalized in different cohorts with different ethnic characteristics and prevalence of MS and other autoimmune diseases.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of antinuclear antibody in patients with multiple sclerosis: a case-control study

Alnajashi

Alshamrani

2021

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

Background Antinuclear antibody (ANA) is a common test for excluding alternative diagnoses. However, the significance of ANA testing in patients with multiple sclerosis (MS) remains unclear. Objectives To compare the prevalence of positive ANA antibody and its titer between patients with MS (cases) and non-MS patients who attended neurology clinics (control) in Saudi Arabia. Methods A case-control review of ANA results for all patients who attended a neurology MS clinic. We compared a convenience sample of patients with MS with individuals with general neurology problems and no known autoimmune diseases. Results There were 115 and 103 participants in the MS and control group, respectively. The mean age in the MS and control group was 33.76 ± 8.96 years and 34.95 ± 8.56 years, respectively. In the MS group, 25.22%, 60%, 11.30%, and 3.48% were negative, mildly positive, moderately positive, and strongly positive for ANA, respectively. In the control group, there were 34.95%, 54.37%, and 10.68% were negative, mild positive, and moderate positive, respectively. There were numerically, but not significantly, more positive cases in the MS group (74.78%) than in the control group (65.05%) (p = .117). Conclusion ANA testing in routine MS screening for excluding alternative diagnoses should be discouraged unless there is a remarkable history or clinical examination finding. Mild positive ANA is common among patients with MS and does not significantly differ from the general population.

show abstract

Do elevated autoantibodies in patients with multiple sclerosis matter?

Cited by 7 publications

References 52 publications

Clinical significance and prognostic value of serum autoantibody tests in multiple sclerosis

Clinical significance and prognostic value of serum autoantibody tests in multiple sclerosis

The prevalence of autoimmune diseases in patients with multiple sclerosis: A cross-sectional study in Qom, Iran, in 2018

Prevalence of antinuclear antibody in patients with multiple sclerosis: a case-control study

Contact Info

Product

Resources

About